|
SE9603726D0
(sv)
*
|
1996-10-11 |
1996-10-11 |
Astra Ab |
Novel compounds
|
|
WO1999039740A2
(en)
*
|
1998-02-03 |
1999-08-12 |
Inex Pharmaceuticals Corporation |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
US6410328B1
(en)
|
1998-02-03 |
2002-06-25 |
Protiva Biotherapeutics Inc. |
Sensitizing cells to compounds using lipid-mediated gene and compound delivery
|
|
IL131887A0
(en)
*
|
1999-09-14 |
2001-03-19 |
Dpharm Ltd |
Phospholipid prodrugs of anti-proliferative drugs
|
|
CN1414857A
(zh)
*
|
1999-12-29 |
2003-04-30 |
加利福尼亚大学董事会 |
耐药性人类免疫缺陷性病毒感染的治疗
|
|
EP1460082A1
(en)
*
|
2003-03-19 |
2004-09-22 |
Heidelberg Pharma Holding GmbH |
Phospholipid esters of clofarabine derivatives
|
|
EP1838283B1
(en)
*
|
2004-11-03 |
2008-12-31 |
Liplasome Pharma A/S |
Lipid-based drug delivery systems containing unnatural phospholipase a2 degradable lipid derivatives and the therapeutic uses thereof
|
|
EP1812012A4
(en)
|
2004-11-15 |
2010-02-17 |
Ceptyr Inc |
PROTEIN TYROSINE PHOSPHATASE INHIBITOR AND METHOD FOR THEIR USE
|
|
ES2401285T3
(es)
|
2004-12-16 |
2013-04-18 |
The Regents Of The University Of California |
Fármacos con el pulmón como diana
|
|
JP2009530318A
(ja)
*
|
2006-03-23 |
2009-08-27 |
リプラサム ファーマ アー／エス |
加水分解時に分子内環化反応を行うホスホリパーゼａ２分解性脂質を含む脂質ベース薬剤送達系
|
|
EP2012799B1
(en)
*
|
2006-05-03 |
2016-08-24 |
Chimerix, Inc. |
Metabolically stable alkoxyalkyl esters of antiviral or antiproliferative phosphonates, nucleoside phosphonates and nucleoside phosphates
|
|
WO2009061208A1
(en)
*
|
2007-11-09 |
2009-05-14 |
Pronova Biopharma Norge As |
Lipid compounds for use in cosmetic products, as food supplement or as a medicament
|
|
EP2070938A1
(en)
*
|
2007-12-13 |
2009-06-17 |
Heidelberg Pharma AG |
Clofarabine dietherphospholipid derivatives
|
|
CN102137676A
(zh)
*
|
2007-12-27 |
2011-07-27 |
伊皮芬尼生物科学公司 |
抗病毒化合物
|
|
EP2278963A4
(en)
*
|
2008-01-16 |
2014-09-17 |
Anwar Rayan |
TAXOL DERIVATIVES AND CLOSELY RELATED COMPOUNDS
|
|
EP2147910A1
(en)
*
|
2008-07-15 |
2010-01-27 |
Pronova BioPharma Norge AS |
Novel lipid compounds
|
|
AU2010244136B2
(en)
|
2009-05-08 |
2016-05-12 |
Pronova Biopharma Norge As |
Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
|
|
US8884027B2
(en)
|
2010-10-22 |
2014-11-11 |
University Of Rochester |
Melampomagnolide B derivatives as antileukemic and cytotoxic agents
|
|
NZ610705A
(en)
|
2010-11-05 |
2014-10-31 |
Pronova Biopharma Norge As |
Methods of treatment using lipid compounds
|
|
MX377728B
(es)
|
2013-02-28 |
2025-03-11 |
Pronova Biopharma Norge As |
Composición que comprende un compuesto lípido, un triglicerido y un tensioactivo, y métodos de uso de la misma.
|
|
US9629860B2
(en)
|
2013-03-15 |
2017-04-25 |
The Regents Of The University Of California |
Acyclic nucleoside phosphonate diesters
|
|
BR112016020233B1
(pt)
|
2014-03-14 |
2022-07-19 |
Alltech Inc. |
Composições de compostos seleno orgânicos e seus usos
|
|
WO2016044281A1
(en)
|
2014-09-15 |
2016-03-24 |
The Regents Of The University Of California |
Nucleotide analogs
|
|
CA2968790A1
(en)
|
2014-11-26 |
2016-06-02 |
Vascular Biogenics Ltd. |
Oxidized lipids and treatment or prevention of fibrosis
|
|
US9771385B2
(en)
|
2014-11-26 |
2017-09-26 |
Vascular Biogenics Ltd. |
Oxidized lipids
|
|
EP4667053A2
(en)
|
2015-03-06 |
2025-12-24 |
ATEA Pharmaceuticals, Inc. |
Beta-d-2'-deoxy-2'alpha-fluoro-2'-beta-c-substituted-2-modified-n6-substituted purine nucleotides for hcv treatment
|
|
BR112017023164A2
(en)
|
2015-04-28 |
2018-07-24 |
Pronova Biopharma Norge As |
and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
|
|
WO2017048252A1
(en)
|
2015-09-15 |
2017-03-23 |
Alltech, Inc. |
Compositions of selenoorganic compounds and methods of use thereof
|
|
EP3350191B9
(en)
|
2015-09-15 |
2021-12-22 |
The Regents of the University of California |
Nucleotide analogs
|
|
WO2018013937A1
(en)
|
2016-07-14 |
2018-01-18 |
Atea Pharmaceuticals, Inc. |
Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
|
|
SMT202200072T1
(it)
|
2016-09-07 |
2022-03-21 |
Atea Pharmaceuticals Inc |
Nucleotidi purinici 2'-sostituiti-n6-sostituiti per il trattamento dei virus rna
|
|
SG11202005007VA
(en)
|
2017-12-06 |
2020-06-29 |
Basf As |
Fatty acid derivatives for treating non-alcoholic steatohepatitis
|
|
JP7610208B2
(ja)
*
|
2019-03-22 |
2025-01-08 |
インテグレイテッド ナノセラピューティクス インコーポレイテッド |
足場部分から調製した脂質結合体
|
|
US12049474B2
(en)
|
2019-08-22 |
2024-07-30 |
Emory University |
Nucleoside prodrugs and uses related thereto
|
|
WO2021173713A1
(en)
|
2020-02-27 |
2021-09-02 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against covid-19
|
|
US10874687B1
(en)
|
2020-02-27 |
2020-12-29 |
Atea Pharmaceuticals, Inc. |
Highly active compounds against COVID-19
|
|
ES3015457T3
(en)
|
2020-08-24 |
2025-05-05 |
Gilead Sciences Inc |
Phospholipid compounds and uses thereof
|
|
TW202344257A
(zh)
|
2020-10-16 |
2023-11-16 |
美商基利科學股份有限公司 |
磷脂化合物及其用途
|
|
AU2023310177A1
(en)
|
2022-07-21 |
2025-03-06 |
Antiva Biosciences, Inc. |
Compositions and dosage forms for treatment of hpv infection and hpv-induced neoplasia
|